(Q53676894)

17 May 2018

title

[Metastatic cáncer presentation. Validation of a diagnostic algorithm with 221 consecutive patients] (English)

1 reference

17 May 2018

author name string

Losa Gaspà F

1

1 reference

17 May 2018

Germá JR

2

1 reference

17 May 2018

Albareda JM

3

1 reference

17 May 2018

Fernández-Ortega A

4

1 reference

17 May 2018

Sanjosé S

5

1 reference

17 May 2018

Fernández Trigo V

6

1 reference

17 May 2018

publication date

1 June 2002

1 reference

17 May 2018

published in

Revista Clínica Española

1 reference

17 May 2018

volume

202

1 reference

17 May 2018

issue

6

1 reference

17 May 2018

page(s)

313-319

1 reference

17 May 2018

An analysis of 1539 patients with cancer of unknown primary site

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Cancer of unknown primary site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Unknown primary adenocarcinoma: incidence of overinvestigation and natural history

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

In pursuit of the unknown primary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Diagnostic persistence in working up metastatic cancer with an unknown primary site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Axillary lymph node metastasis from an occult breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Carcinoma of unknown primary: Identification of a treatable subset?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Empiric chemotherapy in patients with carcinoma of unknown primary site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Cancer of unknown primary. A retrospective study based on 109 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Metastatic carcinomas from occult primary tumors. A study of 254 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Cancer of unknown primary site. Deciding how far to carry evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Metastasis of unknown origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Clinical relevance of the i(12p) marker chromosome in germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Breast carcinoma presenting as axillary metastases without evidence of a primary tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Phase II trial of cisplatin for adenocarcinoma of unknown primary site. IKZ/IKO Clinical Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2802%2971065-5

10.1016/S0014-2565(02)71065-5

7 January 2021

Identifiers

DOI

1 reference

17 May 2018

1 reference

17 May 2018